Elsevier

The Lancet

Volume 360, Issue 9339, 5 October 2002, Pages 1071-1073
The Lancet

Research Letters
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

https://doi.org/10.1016/S0140-6736(02)11131-7Get rights and content

Summary

Results of premarketing and postmarketing trials have raised doubts about the cardiovascular safety of the non-steroidal anti-inflammatory drug (NSAID) rofecoxib, especially at doses greater than 25 mg. Between Jan 1, 1999, and June 30, 2001, we did a retrospective cohort study of individuals on the expanded Tennessee Medicaid programme (TennCare), in which we assessed occurrence of serious coronary heart disease (CHD) in non-users (n=202 916) and in users of rofecoxib and other NSAIDs (rofecoxib n=24132, other n=151728). Participants were aged 50–84 years, lived in the community, and had no life-threatening non-cardiovascular illness. Users of high-dose rofecoxib were 1·70 (95% Cl 0·98–2·95, p=0·058) times more likely than non-users to have CHD; among new users this rate increased to 1·93 (1·09–3·42, p=0·024). By contrast, there was no evidence of raised risk of CHD among users of rofecoxib at doses of 25 mg or less or among users of other NSAIDs.

References (5)

There are more references available in the full text version of this article.

Cited by (0)

View full text